NCT07623642 2026-06-03A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.GV20 TherapeuticsPhase 2 Not yet recruiting227 enrolled